Formulation and Evaluation of Ocular In-Situ Gels of Besifloxacin

Abstract

Besifloxacin, a fourth-generation broad-spectrum antibiotic indicated for infective ophthalmitis, is intended to be released over a sustained period using ion-sensitive ocular in situ gels, which were the focus of the current work. The present analysis concludes that designing and creating oral in-situ gels of Besifloxacin requires a careful selection of polymers and medication. According to I.R. and U.V. investigations, the polymer is chosen, sodium alginate and HPMC were compatible with pefloxacin. It was found that the two polymers' different concentrations had an impact on the gel's viscosity, spreadability, and drug release. Gel formulations demonstrated good stability and uniformity. However, the gel formula, which showed the most significant percentage of drug release and favorable rheological characteristics, ended up being the formula of choice. Based on in vitro release investigations. Formulation F3 gives better and quicker patient improvement. When compared to other formulations, the F3 formulation is the most optimal. There is room for additional pharmacokinetic research because the outcomes of the studies that have already been done are encouraging. With this prolonged drug delivery system, the medicine's bioavailability can also be increased, benefiting patient efficacy, compliance, and therapeutic usefulness.